U.S., March 4 -- ClinicalTrials.gov registry received information related to the study (NCT06853769) titled 'Neoadjuvant Therapy for Locally Advanced Rectal Cancer' on Sept. 11, 2024.
Brief Summary: This study aims to evaluate the clinical efficacy and safety of anlotinib in combination with penpulimab and conventional chemoradiotherapy for the neoadjuvant treatment of locally advanced rectal cancer
Study Start Date: Sept. 01, 2024
Study Type: INTERVENTIONAL
Condition:
Colorectal Cancer
Intervention:
DRUG: Anlotinib hydrochloride,Penpulimab
Penpulimab 200mg IV D1 Anlotinib 12mg P.O. QD D1-14
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Published by HT Digital Con...